Dabigatran Etexilate (DE) is a potent, synthetic, non-peptide competitive, rapidly acting oral direct thrombin inhibitor (oral DTI). It is an anticoagulant medication which can be taken by mouth. It is used as an alternative to warfarin.
Dabigatran Etexilate (DE) is the oral pro-drug of the active moiety dabigatran (DAB) and does not possess anticoagulant activity. The pro-drug dabigatran etexilate is used in its salt form dabigatran etexilate mesilate (DEM). That specifically and reversibly inhibits thrombin, the final enzyme in the coagulation cascade. The granted indication is primary prevention of venous thromboembolism (VTE) in patients undergoing elective major orthopedic surgery (MOS). It is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.